登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:603569 证券简称:长久物流 公告编号：2026-002 北京长久物流股份有限公司 部分股份延期购回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 北京长久物流股份有限公司（以下简称"公司"）控股股东吉林省长久实业集团有限公司（以下简 称"长久集团"）持有公司股份371,240,533股，占公司总股本的61.51%；累计质押公司股份187,650,000 股，占其所持公司股份的50.55%，占公司总股本的31.09%。 ● 控股股东长久集团及其一致行动人上海汇瑾资产管理有限公司-汇瑾尊越1号私募证券投资基金（以下 简称"汇瑾尊越1号基金"）、上海牧鑫私募基金管理有限公司－牧鑫鼎泰1号私募证券投资基金（以下简 称"牧鑫鼎泰1号基金"）、新疆新长汇股权投资管理有限责任公司（以下简称"新长汇"）合计持有公司 股份428,859,005股，占公司总股本的71.06%；合计累计质押公司股187,650,000股，占所持公司股份的 43.76 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 （二）业绩预告情况 四、风险提示 （1）经财务部门初步测算，思特威（上海）电子科技股份有限公司（以下简称"公司"）预计2025年度 实现营业收入880,000万元到920,000万元。与上年同期相比，将增加283,185万元到323,185万元，增幅 47%到54%。 （2）预计2025年度实现归属于母公司所有者的净利润97,635万元到103,053万元。与上年同期相比，将 增加58,361万元到63,779万元，增幅149%到162%。 （3）预计2025年度实现归属于母公司所有者的扣除非经常性损益的净利润为96,583万元到102,001万 元，与上年同期相比，将增加57,441万元到62,859万元，增幅147%到161%。如剔除股份支付费用的影 响，归属于母公司所有者的扣除非经常性损益的净利润为102,273万元到107,691万元，与上年同期相 比，将增加52,427万元到57,845万元，增幅105%到116%。 （三） ...

Core Viewpoint - The major shareholder of Shanghai Medicilon Inc., Chen Guoxing, has decided to terminate his share reduction plan early, maintaining his current holdings due to confidence in the company's stable development and changes in personal financial needs [3][6]. Shareholder Holdings - Before the reduction plan, Chen Guoxing held 4,875,154 shares, accounting for 3.63% of the total share capital, while his concerted action partner, Lin Changqing, held a total of 8,806,324 shares, representing 6.55% of the total share capital [2][8]. Reduction Plan Implementation Results - On November 20, 2025, Chen Guoxing announced a plan to reduce his holdings by up to 2,200,000 shares (1.64% of total share capital) within three months, but as of the announcement date, he had not executed any reductions and still held 4,875,154 shares [3][6]. - The decision to terminate the reduction plan was based on Chen's confidence in the company's ongoing stability and changes in his financial situation [3][6]. Future Shareholding Intentions - Following the completion of the reduction plan, Lin Changqing intends to continue holding his shares and will consider reducing his holdings based on personal development needs while adhering to relevant laws and commitments [9][10].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002891证券简称：中宠股份 公告编号：2026-003 债券代码：127076 债券简称：中宠转2 烟台中宠食品股份有限公司关于第四届董事会第二十次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 3、拟回购股份的价格上限：本次回购股份的价格为不超过78.00元/股（含），回购价格上限未超过公 司董事会审议通过回购股份方案前30个交易日公司股票交易均价的150%，具体回购价格将综合回购实 施期间公司二级市场股票价格、财务状况和经营情况确定； 一、董事会会议召开情况 2026年1月23日烟台中宠食品股份有限公司（以下简称"公司"）第四届董事会第二十次会议在公司会议 室以现场加通讯相结合的会议方式召开。会议通知已于2026年1月13日通过专人送达、电子邮件等方式 送达给董事和高级管理人员，本次会议应出席会议董事9人，实际出席会议董事9人，其中伊藤范和先 生、董海风女士、郝宸龙先生以通讯表决方式出席会议，公司董事长郝忠礼先生主持了本次会议，公司 全体高级管理人员列席会议，会议的召开符合《中 ...

Core Points - The company has announced a conditional redemption for its convertible bonds, "Kewo Convertible Bonds," due to the stock price falling below 70% of the conversion price for 30 consecutive trading days [2] - The redemption price is set at 100.26 RMB per bond, including accrued interest and tax [9] - The redemption period is from January 21, 2026, to January 27, 2026, with funds to be disbursed on January 30, 2026 [10] Redemption Terms - Holders of "Kewo Convertible Bonds" have the right to redeem their bonds at the specified price if the company's stock price conditions are met [2][5] - The redemption is not mandatory, allowing bondholders to choose whether to redeem [5] - If bondholders do not redeem during the specified period, they will lose the right to redeem for the current interest year [2] Interest Calculation - The interest for the current period is calculated based on a rate of 1.8% for the fifth year, resulting in approximately 0.26 RMB per bond [4] - The total redemption price is thus 100.26 RMB per bond, which includes the principal and accrued interest [4] Redemption Process - Bondholders must submit their redemption requests through the Shanghai Stock Exchange trading system during the specified redemption period [6][8] - If a redemption request is not successful on the first day, bondholders can continue to submit requests on subsequent days within the redemption period [7] Trading During Redemption Period - "Kewo Convertible Bonds" will continue to trade during the redemption period but will not be convertible into shares [12] - If the total face value of the bonds in circulation falls below 30 million RMB due to redemptions, trading will continue until the end of the redemption period [12]

Group 1: Tax Payment Announcement - The company is required to pay approximately 19.95 million yuan in taxes as notified by the local tax authority, which will be paid within 15 days and does not involve any penalties or late fees [1][2] - The tax payment will be recorded in the company's profit and loss for the fiscal year 2025, impacting the total profit by approximately 19.95 million yuan [2] Group 2: 2025 Annual Performance Forecast - The company forecasts a total revenue of approximately 721.01 million yuan for 2025, an increase of about 30.32 million yuan or 72.57% compared to the previous year [6] - The expected revenue from the anti-HIV innovative drug is projected to be approximately 285.31 million yuan, reflecting a year-on-year increase of 90.34% [6] - The company anticipates a net loss attributable to shareholders of approximately 16 million to 24 million yuan, which represents a reduction in loss of about 12.52 million to 11.72 million yuan, a decrease of approximately 88.67% to 83.00% year-on-year [7] Group 3: Clinical Trial Application for ACC085 Injection - The company has received acceptance for the clinical trial application of ACC085 injection, a new HIV-1 capsid inhibitor, which is intended for pre-exposure prophylaxis (PrEP) [11][14] - ACC085 is designed to inhibit HIV-1 replication and has shown promising antiviral activity in preclinical studies [14][15] - The global HIV infection situation remains severe, with 40.8 million existing HIV-infected individuals, highlighting the importance of effective prevention strategies [16]

Group 1 - The company has appointed Xu Ruixing as the new signing auditor for the 2025 financial year, replacing Yu Yongchun who has left the firm [2][3] - The audit firm, Beijing Dehao International, will continue to provide financial and internal control audits for the company in 2025 [2][3] - The transition of responsibilities during the change of signing auditor has been orderly, ensuring no adverse impact on the 2025 financial report audit [6] Group 2 - The company and its subsidiaries need to pay a total of 50.79 million yuan in tax and late fees, with the company itself responsible for 2.70 million yuan and subsidiaries for 48.09 million yuan [8][9] - This tax payment will be recorded in the company's 2025 profit and loss statement, but it will not affect prior financial data adjustments [9] - The tax payment will not impact the company's normal operations [9]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002155 证券简称：湖南黄金 公告编号：临2026-03 湖南黄金股份有限公司 2025年度业绩预告 本公司董事会及全体董事、高级管理人员保证公告内容的真实、准确和完整，对公告的虚假记载、误导 性陈述或者重大遗漏负连带责任。 一、本期业绩预计情况 1、业绩预告期间：2025年1月1日至2025年12月31日。 2、业绩预告情况：预计净利润为正值且属于同向上升50%以上情形 （1）以区间数进行业绩预告的 单位：万元 ■ 注：因公司2025年6月完成资本公积金转增股本，故对上年同期基本每股收益进行重新计算。 二、与会计师事务所沟通情况 公司本次业绩预告的相关财务数据未经会计师事务所审计。公司已就业绩预告有关事项与会计师事务所 进行了预沟通，公司与会计师事务所在本次业绩预告方面不存在分歧。 三、业绩变动原因说明 报告期内，业绩上涨主要是公司金、锑、钨产品销售价格同比上涨。 四、其他相关说明 本次业绩预告是公司财务部门初步测算的结果，未经审计机构审计。具体财务数据以公司披露的2025年 年度报告为准。敬请广大投资者谨慎决策，注意投资风险。 特此公告。 湖 ...

Core Viewpoint - The company, 康希通信科技 (Shanghai) Co., Ltd., and its subsidiary GRAND CHIP LABS, INC. have not violated Section 337 of the Tariff Act of 1930, as per the preliminary ruling by the ITC administrative judge, thus not infringing on Skyworks' patents [2][4][5]. Group 1: Case Background - The case is currently at the stage of the ITC's preliminary ruling regarding a Section 337 investigation initiated by Skyworks Solutions, Inc. and its affiliates, claiming patent infringement related to specific RF front-end modules (FEMS) [2][3]. - Skyworks filed a lawsuit in May 2024 against 康希通信科技 (Shanghai) Co., Ltd. and GRAND CHIP LABS, INC. for patent infringement, which led to the initiation of the ITC investigation in July 2024 [2][3]. Group 2: Preliminary Ruling Results - On January 24, 2026, the ITC administrative judge issued a preliminary ruling stating that 康希通信科技 (Shanghai) Co., Ltd. and GRAND CHIP LABS, INC. did not infringe on two of Skyworks' patents (US 9,917,563 and US 8,717,101) [4]. - Three other patents (US 9,450,579, US 9,148,194, and US 7,409,200) were withdrawn by Skyworks during the evidence disclosure phase, leading to their termination in the investigation [4][5]. Group 3: Company Response and Impact - The company emphasizes its commitment to intellectual property management and protection, maintaining a complete intellectual property system and conducting thorough IP checks before technology implementation [6][7]. - The favorable preliminary ruling is seen as a significant legal support for the company's product exports to the U.S. market, although both parties retain the right to request a review within the statutory period [7].

Core Viewpoint - The company has received approval for the production of Loxoprofen Sodium Gel Patch, which is expected to enhance its product line in orthopedic medications and improve its competitive position in the market [1][3]. Group 1: Drug Registration and Details - The company's subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., has obtained the Drug Registration Certificate for Loxoprofen Sodium Gel Patch from the National Medical Products Administration [1]. - Loxoprofen Sodium Gel Patch is indicated for the treatment of osteoarthritis, muscle pain, and swelling pain after injuries, with significant anti-inflammatory and analgesic effects [1]. - The total investment in this drug project, including research and development, has reached 7.0366 million yuan (approximately 1.01 million USD) as of the announcement date [1]. Group 2: Market Situation of Similar Drugs - A total of 15 companies in China have obtained drug registration certificates for Loxoprofen Sodium Gel Patch, including listed companies such as Jiutian Pharmaceutical, Darentang, and China Resources Sanjiu [2]. - According to Moen Pharmaceutical data, the total sales of Loxoprofen Sodium Gel Patch in hospitals for the first three quarters of 2025 reached 1.349 billion yuan (approximately 190 million USD), with retail sales in physical pharmacies amounting to 142 million yuan (approximately 20 million USD) in the first half of 2025 [2]. - Projected sales for 2024 are expected to be 1.709 billion yuan (approximately 240 million USD) in hospitals and 280 million yuan (approximately 40 million USD) in retail pharmacies [2]. Group 3: Impact on the Company - The approval of Loxoprofen Sodium Gel Patch will enrich the company's product line for orthopedic diseases, which already includes products like Xuanqi Jianguo Tablets and Tenghuang Jianguo Tablets [3]. - This new product is anticipated to enhance the company's competitiveness in the orthopedic medication market and improve overall profitability [3]. - The company emphasizes the importance of drug research and development while maintaining strict quality control in the manufacturing and sales processes [3].